SCHEMBL4019736

SCHEMBL4019736

CC(C)(C)OC(=O)NC1CCN(S(=O)(=O)c2ccc(CNC(=O)c3ccc(Cl)cc3)s2)CC1.N#Cc1ccc(N2CCN(S(=O)(=O)c3ccc(CNC(=O)c4ccc(Cl)cc4)s3)CC2)nc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK9 P45984 1/20 0.48
MAPK10 P53779 1/20 0.48
MAPK8 P45983 1/20 0.46
NAMPT P43490 2/20 0.44
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
CCR6 P51684 2/20 0.41
CXCR3 P49682 1/20 0.39
RET P07949 1/20 0.38
KDM4D Q6B0I6 1/20 0.38
AAK1 Q2M2I8 1/20 0.37
JAK3 P52333 1/20 0.36
BTK Q06187 1/20 0.36
CHRM4 P08173 1/20 0.36
PRKAA2 P54646 2/20 0.36
PRKAB2 O43741 1/20 0.36
PRKAG1 P54619 1/20 0.36
PRKAA1 Q13131 1/20 0.36
PRKAG3 Q9UGI9 1/20 0.36
PRKAG2 Q9UGJ0 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2425191 0.88 MAPK9 (0.51) MAPK9MAPK10MEN1KMT2ACCR6
SCHEMBL2424021 0.86 MAPK9 (0.59) MAPK9MAPK10MAPK8NAMPTMEN1
SCHEMBL3479771 0.77 L3MBTL1 (0.55) MAPK9MAPK10MEN1KMT2ASMN1; SMN2
SCHEMBL7078845 0.75 RET (0.57) RETKDM4DAAK1JAK3BTK
SCHEMBL27493171 0.75 MAPK9 (0.41) MAPK9MAPK10CXCR3CHRM4PANK3
SCHEMBL6437014 0.74 MAPK9 (0.65) MAPK9MAPK10MEN1KMT2AHTT
SCHEMBL4316209 0.74 KMT2A (0.53) MAPK9MAPK10NAMPTMEN1KMT2A
SCHEMBL2420724 0.74 SMN1; SMN2 (0.58) MAPK9MAPK10MEN1KMT2AHTT
SCHEMBL3480063 0.74 MAPK9 (0.51) MAPK9MAPK10MEN1KMT2APANK3
SCHEMBL2425741 0.73 MAPK9 (0.59) MAPK9MAPK10MEN1KMT2AHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1218374-A1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2002-07-03 EP claimed
WO-2001023378-A1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-05 WO claimed
US-20090176762-A1 JNK Inhibitors for Treatment of Skin Diseases LABORATOIRES SERONO SA (CH) 2009-07-09 US disclosed
EP-1904181-A2 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETREOSIS LABORATOIRES SERONO S.A. (CH) 2008-04-02 EP disclosed
WO-2007011762-A2 JNK INHIBITORS FOR THE TREATMENT OF ENDOMETREOSIS LABORATOIRES SERONO S.A. (CH) 2007-01-25 WO disclosed
EP-1218374-A1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES Applied Research Systems ARS Holding N.V. (AN) 2002-07-03 EP disclosed
WO-2001023378-A1 PHARMACEUTICALLY ACTIVE SULFONAMIDE DERIVATIVES APPLIED RESEARCH SYSTEMS ARS HOLDING N.V. (AN) 2001-04-05 WO disclosed
WO-1994000119-A1 AMINOBUTANOIC ACID COMPOUNDS HAVING METALLOPROTEASE INHIBITING PROPERTIES GLAXO INC. (US) 1994-01-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090176762-A1 JNK Inhibitors for Treatment of Skin Diseases MAPKAPK2, JUN, MAP3K13 MAPK9 33/4885MAPK10 35/4885MAPK8 31/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.